With the rapid pace of anti-tumor drug development, there evolve urgent requirements for sophisticated animal models to more accurately recapitulate in vivo pharmacodynamics/pharmacokinetic/toxicity profile. Currently, many oncology studies have been explored in human tumor xenografts growing in immunodeficient mice. However, for immunomodulatory agents like immune checkpoint blockers, this approach can be inadequate due to the lack of human immune system as well as tumor microenvironment. While it can be extremely expensive and time-consuming to develop a fully human immune system via engraftment of human HSC/PBMC, we offer a novel alternative of human knock-in (KI) immune checkpoint genes to test drugs that target human immune cells.
Features of Humanized Immune Checkpoint Mice Models
TIGIT and PD-L1 Blockades Synergistically Elicit Tumor Rejection (A-C) BALB/c mice were inoculated subcutaneously with CT26 colorectal carcinoma cells in their right thoracic flanks.
BioCytoceuticals leads the industry in cellular therapy with commitment to providing the most appropriate solutions to address the needs of our clients. Our expert team of scientists applies comprehensive methods and the most detail-oriented scrutiny to ensure only top-tier outcome is submitted. We provide comprehensive services and products for customer, including humanized mouse models and their related services.
If you have any special enquiries regarding our Immune Checkpoint Inhibitor service, please do not hesitate to contact us. Our highly professional technical supporting staffs will make sure your requests are faithfully received. We are looking forward to earning your business.
Inquiry
